Pieris Pharmaceuticals is proud to partner with industry leaders in immuno-oncology and respiratory medicines. Read how these key partnerships are helping us produce superior outcomes for patients.
This research collaboration will enable Pieris to combine its robust discovery engine with Genentech’s targets, as well as preclinical and clinical development expertise to create novel therapies. Pieris will be responsible for discovery research and early preclinical development for any programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of those programs. Genentech has the option to select additional targets in return for an option exercise fee.
In partnership with Servier, we are focused on developing PRS-344, a potential best-in-class, PD-L1/4-1BB bispecific. Pieris holds exclusive commercialization rights for PRS-344 in the United States and will receive royalties on ex-U.S. sales by Servier for this program.
This collaboration aims to investigate several targeted, bispecific immuno-oncology treatments for solid tumors and blood cancers. Together, we will develop antibody-Anticalin fusion proteins that leverages Pieris’ suite of agonistic costimulatory Anticalin proteins and Seagen’s portfolio of cancer targets and tumor-specific antibodies. The bispecific drugs will be designed to activate a patient’s immune cells locally in the tumor microenvironment.
Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Both parties are collaborating during the investigational new drug (IND)-enabling stage, and Boston Pharmaceuticals is responsible for further development of the program.
